Subtype
Adult-Type Diffuse Glioma
CI-CAN-00009389Explore in graph →
510 active trials2 approved drugs70 evidence items
- OncoTree
- ADIFG
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009389Explore in graph →
Clinical trials
1,869 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (295)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04604158 | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | completed | N/A | 38 | Gillian GreshamOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT01591577 | Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03139916 | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04143425 | Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma | completed | — | 15 | Ho Sung KimOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT03776071 | A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 | completed | Phase 3 | 260 | Denovo Biopharma LLCINDUSTRY | 3 | Apr 22, 2024 | clinicaltrials |
| NCT02654964 | Cancer Stem Cell High-Throughput Drug Screening Study | completed | Phase 1 | 9 | Swedish Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT03043391 | Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children | completed | Phase 1 | 8 | Istari Oncology, Inc.INDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT00589875 | Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma(BrTK02) | completed | Phase 2 | 52 | Candel Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03454295 | Easing Psychosocial Burden for Informal Caregivers | completed | Early Phase 1 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03466450 | Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma(GEINOGLAS) | completed | Phase 1 / Phase 2 | 75 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | completed | Phase 1 / Phase 2 | 160 | NewLink Genetics CorporationINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03770468 | Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma | completed | — | 599 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
| NCT03712293 | ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy | completed | N/A | 9 | InSightecINDUSTRY | 1 | Mar 5, 2024 | clinicaltrials |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | completed | Phase 2 / Phase 3 | 101 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT02869243 | A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients | completed | Phase 1 | 15 | StemgenINDUSTRY | 3 | Feb 16, 2024 | clinicaltrials |
| NCT04810182 | Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS | completed | — | 192 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT00704288 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme | completed | Phase 2 | 222 | ExelixisINDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01922076 | Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Jan 31, 2024 | clinicaltrials |
| NCT02206230 | Trial of Hypofractionated Radiation Therapy for Glioblastoma | completed | Phase 2 | 133 | AHS Cancer Control AlbertaOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01811498 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | completed | Phase 1 / Phase 2 | 31 | Northwell HealthOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03616860 | Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma | completed | N/A | 14 | InSightecINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02457845 | HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | completed | Phase 1 | 13 | Gregory K. Friedman, MDOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04552886 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | completed | Phase 1 | 17 | The Cooper Health SystemOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT02684058 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | completed | Phase 2 | 151 | Novartis PharmaceuticalsINDUSTRY | 20 | Dec 13, 2023 | clinicaltrials |
| NCT01421524 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | completed | Phase 1 | 271 | CelgeneINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02060890 | Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma(TGEN) | completed | — | 20 | University of California, San FranciscoOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01957956 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02315534 | A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma | completed | Phase 1 / Phase 2 | 34 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Nov 15, 2023 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03557372 | Mathematical Model-Adapted Radiation In Glioblastoma | completed | N/A | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT02658981 | Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) | completed | Phase 1 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01491893 | PVSRIPO for Recurrent Glioblastoma (GBM)(PVSRIPO) | completed | Phase 1 | 61 | Istari Oncology, Inc.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05873946 | Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery(2D-ioUS-Glio) | completed | — | 99 | Hospital del Rio HortegaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04119674 | Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 33 | Zhejiang Cancer HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01493219 | Biomarkers for Prognosis of Glioblastoma (GBM) | completed | — | 19 | University of NebraskaOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT00751270 | Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas(BrTK01) | completed | Phase 1 | 15 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 25, 2023 | clinicaltrials |
| NCT01259869 | A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression | completed | Phase 2 | 34 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT05039346 | Quality of Life and Patient Needs in Advanced High Grade Gliomas | completed | — | 55 | Henry Ford Health SystemOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT02619864 | mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme | completed | Phase 1 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03538587 | Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers | completed | N/A | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02330991 | A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 204 | Beijing Sanbo Brain HospitalOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT04814329 | Glioblastoma Response Prediction to Apatinib | completed | — | 18 | Beijing Sanbo Brain HospitalOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05718466 | Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | completed | Phase 3 | 35 | Henry Ford Health SystemOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT01290692 | Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma | completed | Phase 2 | 14 | TVAX BiomedicalINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated May 21, 2024source: clinicaltrials